Latham & Watkins has advised GSK on a strategic research collaboration and option agreement with Engitix, a biotechnology company pioneering extracellular matrix (ECM)-driven drug discovery, to identify and validate novel therapeutic targets driving liver fibrosis regression.
The Latham team was led by London partner Lydia Torne, with associate Luke Nauth.
LEGAL DESIRE NEWSLETTER
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.
